# A Phase 1, Study to Evaluate HTI-2088 Tablet

> **NCT03203811** · PHASE1 · COMPLETED · sponsor: **Hengrui Therapeutics, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** HTI-2088
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03203811
- **Lead sponsor:** Hengrui Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-17
- **Primary completion:** 2017-10-23
- **Final completion:** 2017-10-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03203811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03203811, "A Phase 1, Study to Evaluate HTI-2088 Tablet". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03203811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*